Cortexyme, Inc. | Business Contracts

Second Amendment to License Agreement, dated as of July 22, 2022, by and between Purdue Research Foundation and Novosteo, Inc (Filed With SEC on November 9, 2022)

Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Dirk Thye, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)

Sublease Agreement, by and between Cortexyme, Inc. and ICON Clinical Research, LLC, dated as of May 5, 2022 (Filed With SEC on August 9, 2022)

Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, by and among Cortexyme, Inc., Novosteo Inc., Quince Merger Sub I, Inc., Quince Merger Sub II, LLC and... (Filed With SEC on May 12, 2022)

Open Market Sale AgreementSM dated December 23, 2021, by and between Cortexyme, Inc. and Jefferies LLC (Filed With SEC on December 23, 2021)

Form of Stock Purchase Agreement (Filed With SEC on February 6, 2020)

Form of Indemnification Agreement between Cortexyme, Inc. and each of its officers and directors (Filed With SEC on April 29, 2019)

Separation Agreement, by and between Cortexyme, Inc. and Michael Detke, dated as of May 2, 2022 (Filed With SEC on August 9, 2022)

Employment Offer Letter, by and between Cortexyme, Inc. and Brendan Hannah, dated May 9, 2022 (Filed With SEC on August 9, 2022)

Employment Offer Letter, by and between Cortexyme, Inc. and Karen Smith, dated May 9, 2022 (Filed With SEC on August 9, 2022)

Employment Offer Letter, by and between Cortexyme, Inc. and Dirk Thye, dated May 9, 2022 (Filed With SEC on August 9, 2022)

Separation Agreement, by and between Cortexyme, Inc. and Caryn G. McDowell, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)

Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Brendan Hannah, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)

Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Karen Smith, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)

Separation Agreement, by and between Cortexyme, Inc. and Christopher Lowe, dated as of June 10, 2022 (Filed With SEC on August 9, 2022)

Consent to Sublease, by and between Cortexyme, Inc. and ICON Clinical Research, LLC, dated as of June 8, 2022 (Filed With SEC on August 9, 2022)

Separation Agreement, by and between Cortexyme, Inc. and Leslie Holsinger, dated as of July 31, 2022 (Filed With SEC on August 9, 2022)

Amended and Restated Outside Director Compensation Policy (Filed With SEC on August 9, 2022)

License Agreement dated June 3, 2020, by and between Purdue Research Foundation and Novosteo Inc (Filed With SEC on August 9, 2022)

Amendment No. 1 to License Agreement dated March 21, 2022 by and between Purdue Research Foundation and Novosteo Inc (Filed With SEC on August 9, 2022)

Severance Agreement, dated February 1, 2022, between Stephen Dominy and the Registrant (Filed With SEC on March 1, 2022)

Severance Agreement, dated February 1, 2022, between Casey Lynch and the Registrant (Filed With SEC on March 1, 2022)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Ted Monohon, dated as of September 21, 2021 (Filed With SEC on October 29, 2021)

Third Amendment to Sub-Sublease by and between Cortexyme, Inc. and Verily Life Sciences LLC dated July 15, 2021 (Filed With SEC on August 6, 2021)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Michael Detke, dated as of May 21, 2021 (Filed With SEC on August 6, 2021)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Leslie Holsinger, dated as of May 18, 2021 (Filed With SEC on August 6, 2021)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Christopher Lowe, dated as of May 18, 2021 (Filed With SEC on August 6, 2021)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Caryn McDowell, dated as of May 18, 2021 (Filed With SEC on August 6, 2021)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Casey C. Lynch, dated as of May 19, 2021 (Filed With SEC on August 6, 2021)

Change in Control and Severance Agreement, by and between Cortexyme Inc. and Stephen S. Dominy, M.D., dated as of May 19, 2021 (Filed With SEC on August 6, 2021)

Description of Securities (Filed With SEC on March 1, 2021)

Separation Agreement by and between Kristen Gafric and Cortexyme, Inc., dated as of April 27, 2020 (Filed With SEC on August 14, 2020)

Second Amendment to Sub-Sublease by and between Cortexyme, Inc. and Verily Life Sciences LLC dated May 26, 2020 (Filed With SEC on August 14, 2020)

Form of Executive Change in Control and Severance Agreement (Filed With SEC on May 21, 2020)

Description of Securities (Filed With SEC on March 16, 2020)

Amendment No. 1 to Sub-Sublease by and between Cortexyme, Inc. and Verily Life Sciences LLC dated April 2, 2019 (Filed With SEC on August 9, 2019)

2019 Employee Stock Purchase Plan (Filed With SEC on April 29, 2019)

2019 Equity Incentive Plan and forms of stock award agreements thereunder (Filed With SEC on April 29, 2019)

Specimen Stock Certificate (Filed With SEC on April 29, 2019)

Form of Underwriting Agreement (Filed With SEC on April 29, 2019)

Amended and Restated Investors Rights Agreement by and among Cortexyme, Inc. and certain holders of its capital stock, dated May 23, 2018 (Filed With SEC on April 12, 2019)

Sub-Sublease Agreement by and between Cortexyme, Inc. and Verily Life Sciences LLC, dated June 18, 2018 (Filed With SEC on April 12, 2019)

2014 Stock Plan, as amended as of November 28, 2018, and related forms of stock award agreements (Filed With SEC on April 12, 2019)

Executive Incentive Bonus Plan (Filed With SEC on April 12, 2019)

Cortexyme, Inc. (44)